nuclear receptor subfamily 5 group A member 2Genealiases: B1F · B1F2 · CPF · FTF · FTZ-F1 · FTZ-F1beta
Q-omics provides the consensus-scored NR5A2 profile across patient tissues and cancer cell-line models. NR5A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NR5A2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NR5A2 RNA expression shows 18,505 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where NR5A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR5A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR5A2 survival associations across molecular data types. NR5A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR5A2 RNA expression–survival associations across cancer types. High NR5A2 expression shows unfavorable associations in KIRP, UVM, STAD and SCLC, but favorable associations in HNSC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NR5A2 RNA expression.
This table summarizes NR5A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NR5A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR5A2 shows lower tumor expression in COAD, LUSC, KICH, BRCA and LUAD and higher tumor expression in KIRC. The COAD box plot shows higher NR5A2 RNA expression in normal versus tumor tissue (log2 FC = −2.502, t-test p < 0.001).
This table shows molecular features associated with NR5A2 in patient tissues and cancer cell lines. In patient samples, NR5A2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NR5A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
